Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Recruiting now

Conditions studied: Hepatocellular Carcinoma (HCC)

In brief

Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.

Key facts

Study ID

NCT07265271

Run by

City of Hope Medical Center

People needed

600

Starts

2025-01-15

Expected to finish

2028-06-18

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults aged 18 to 100 years.
• A histologically confirmed diagnosis of hepatocellular carcinoma.
• A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma.
• Healthy volunteers without known liver disease or malignancy.
• Received standard diagnostic and staging procedures as per local guidelines
• Availability of blood or other biospecimens.
• Ability to provide written informed consent.

You may not qualify if…

• Lack of or inability to provide informed consent
• History of other active malignancies within the past 5 years
• Previous liver transplantation
• Severe systemic infection or inflammatory disease at the time of enrollment
• Inadequate sample quality or quantity

Where it is running

• City of Hope Medical Center — Duarte, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.